Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654214 | 1.00 | PDE10A (0.46) | PDE10APDGFRBENPP1ADRA1DADRA1B | |
| SCHEMBL5653867 | 1.00 | PDE10A (0.46) | PDE10APDGFRBENPP1ADRA1DADRA1B | |
| SCHEMBL8231232 | 1.00 | PDE10A (0.46) | PDE10APDGFRBENPP1ADRA1DADRA1B | |
| SCHEMBL14341442 | 0.84 | EHMT2 (0.51) | PDE10APDGFRBENPP1ADRB2PDE3A | |
| SCHEMBL4717969 | 0.84 | EHMT2 (0.51) | PDE10APDGFRBENPP1ADRB2PDE3A | |
| SCHEMBL4164651 | 0.82 | PDE10A (0.46) | PDE10AENPP1ADRA1DADRA1BADRA1A | |
| SCHEMBL4791600 | 0.82 | PDE10A (0.46) | PDE10AENPP1ADRA1DADRA1BADRA1A | |
| SCHEMBL5654216 | 0.80 | PDE10A (0.38) | PDE10APDGFRBDPP4 | |
| SCHEMBL5653295 | 0.80 | PDE10A (0.38) | PDE10APDGFRBDPP4 | |
| SCHEMBL5653869 | 0.80 | PDE10A (0.38) | PDE10APDGFRBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | PDE10A 2/4885PDGFRB 3311/4885ENPP1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.